QDX HealthID, currently in beta release, is a SaaS-based platform allowing companies and individuals to view and select a particular Covid-19 test kit, authenticate and record their test results in a secure way, and then share authenticated results with friends, family—or any other third party to share negative virus statuses
QDX HealthID Incorporated, a wholly owned subsidiary of Quantum Materials Corp. (OTC Bulletin Board: QTMM) – today announced that, in conjunction with its parent, has signed a distribution agreement with Innova Medical Group Inc. (IMG), a wholly owned subsidiary of Pasaca Capital, Inc., for the inclusion of IMG’s rapid-result antigen and antibody tests, and PCR swab tests, in the QDX™ HealthID ecosystem of COVID-19 testing solutions.
QDX™ HealthID, currently in beta release, is a SaaS-based platform allowing companies and individuals to view and select a particular COVID-19 test kit, authenticate and record their test results in a secure way, and then share authenticated results with friends, family—or any other third party to share negative virus statuses.
With this agreement, the QDX™ HealthID test kit ecosystem now includes 6 out of 12 rapid-result antibody tests currently granted the Food & Drug Administration’s (FDA) Emergency Use Authorization (EUA). These test kits, and same-day antigen tests may be performed at point-of-care facilities and best support the most effective COVID-19 testing strategies that eliminate delays in receiving test results, which often render testing and tracking efforts completely ineffective.
The agreement between QDX™ HealthID and IMG allows users registered on the QDX™ HealthID platform to use an IMG-supplied test kit — when a healthcare provider prescribes it. The agreement is non-exclusive and allows other registered test kits and diagnostic services to be used by QDX™ HealthID customers.
Innova Medical Group Inc. (IMG) is a wholly owned subsidiary of Pasaca Capital. It brings the most innovative medical technologies to the global market to benefit as many people as possible. Pasaca Capital Inc. and Innova Medical Group Inc. were founded by Dr. Charles Huang.
“We are excited to be working with Innova Medical Group and adding its test kit portfolio to our QDX™ HealthID ecosystem,” says Stephen B. Squires, CEO of QDX HealthID Incorporated. “This ecosystem now offers a comprehensive set of COVID-19 testing options allowing QDX™ HealthID to address the health safety needs of myriad industries and testing environments.”
“We are confident that adding QDX HealthID Incorporated to Innova Medical Group’s rapid test kit distribution group will ensure that even more, superior testing solutions will continue being a key solution for effectively detecting and tracking the COVID-19 virus, worldwide,” shares Dr. Charles Huang, Founder and Partner of Pasaca Capital Inc. “As industry leaders specializing in research, development, and the production of point-of-care testing, in-vitro diagnostic devices, and reagents, our test kit developers are all well-known as makers of superior technologies providing better healthcare solutions to benefit people everywhere.”
Source: Company Press Release